Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVM-100
- Development stage
- Preclinical
- Lead developer
- Oxford Vacmedix
- Modality
- Vaccines & Immunotherapeutics
01
Overview
OVM-100 is a therapeutic cancer vaccine developed by Oxford Vacmedix using their proprietary recombinant overlapping peptide (ROP) platform, targeting HPV antigens for the treatment of cervical cancer and head and neck cancer. It stimulates broad and strong T-cell immunity by presenting overlapping peptide fragments of HPV proteins to enhance cellular immune responses against cancer cells. The vaccine is intended for use as monotherapy or in combination with immune-oncology agents, with preclinical development ongoing and plans for Phase 1 trials.[2][3][7][8]
Beyond the preview
Go deeper on OVM-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OVM-100.